Literature DB >> 2514169

Antibodies against p40tax gene product of human T-lymphotropic virus type-I (HTLV-I) under various conditions of HTLV-I infection.

S Kamihira1, K Toriya, T Amagasaki, S Momita, S Ikeda, Y Yamada, M Tomonaga, M Ichimaru, K Kinoshita, T Sawada.   

Abstract

We investigated antibodies against pX gene product, p40tax, by ELISA using recombinant p40tax protein in HTLV-I seropositive carriers as well as patients with adult T cell leukemia (ATL) and HTLV-I-associated myelopathy (HAM). Seventy (49.0%) out of 143 HTLV-I healthy carriers were found to be positive for antibody against p40tax antigen and the follow-up samples at two-year intervals revealed constant reactivity by ELISA in each carrier. The onset of antibody production was delayed 4 to 12 weeks as compared with anti-HTLV-I in primary infection cases. The anti-p40tax-positive rate (90%) in HAM patients was significantly higher than that of healthy carriers, acute and chronic ATL patients and their family members. Furthermore, HAM patients and a few healthy carriers showed high reactivities by ELISA. Children from mothers with anti-p40tax showed a higher anti-HTLV-I-positive rate than that of children from mothers without anti-p40tax (54.5% versus 12.5%). Two men without anti-p40tax and one female with low anti-p40tax developed ATL during follow-up studies. These results suggest that HTLV-I carriers could be divided into 2 or 3 sub-populations according to antibody response to p40tax. A smaller population with anti-p40tax, especially a high antibody reactivity, could have a high risk of developing HAM and of transmission from mother to child. In addition, ATL may occur in a population with low or absent anti-p40tax.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2514169      PMCID: PMC5917912          DOI: 10.1111/j.1349-7006.1989.tb02260.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  18 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma.

Authors:  K Usuku; S Sonoda; M Osame; S Yashiki; K Takahashi; M Matsumoto; T Sawada; K Tsuji; M Tara; A Igata
Journal:  Ann Neurol       Date:  1988       Impact factor: 10.422

4.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

5.  Monoclonal antibody reactive with both p28 and p19 of adult T-cell leukemia virus-specific polypeptides.

Authors:  Y Tanaka; Y Koyanagi; T Chosa; N Yamamoto; Y Hinuma
Journal:  Gan       Date:  1983-06

6.  Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor.

Authors:  J Fujisawa; M Seiki; T Kiyokawa; M Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

7.  Preleukemic state of adult T cell leukemia: abnormal T lymphocytosis induced by human adult T cell leukemia-lymphoma virus.

Authors:  K Kinoshita; T Amagasaki; S Ikeda; J Suzuyama; K Toriya; K Nishino; M Tagawa; M Ichimaru; S Kamihira; Y Yamada
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

8.  A new agglutination test for serum antibodies to adult T-cell leukemia virus.

Authors:  M Ikeda; R Fujino; T Matsui; T Yoshida; H Komoda; J Imai
Journal:  Gan       Date:  1984-10

9.  Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells.

Authors:  J G Sodroski; C A Rosen; W A Haseltine
Journal:  Science       Date:  1984-07-27       Impact factor: 47.728

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  8 in total

1.  Transmission of human T-cell lymphotropic virus type 1 tax to rabbits by tax-only-positive human cells.

Authors:  D Zucker-Franklin; B A Pancake; P Lalezari; M Khorshidi
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 2.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

Review 3.  Non-HIV retroviral associations with rheumatic disease.

Authors:  D Zucker-Franklin
Journal:  Curr Rheumatol Rep       Date:  2000-04       Impact factor: 4.592

4.  Episodic occurrence of antibodies against the bovine leukemia virus Rex protein during the course of infection in sheep.

Authors:  M A Powers; D Grossman; L C Kidd; K Radke
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Human T-cell lymphotropic virus type 1 tax among American blood donors.

Authors:  D Zucker-Franklin; B A Pancake
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

6.  Detection of antibodies to trans-activator protein (p40taxI) of human T-cell lymphotropic virus type I by a synthetic peptide-based assay.

Authors:  D L Rudolph; J E Coligan; R B Lal
Journal:  Clin Diagn Lab Immunol       Date:  1994-03

7.  The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients.

Authors:  B A Pancake; D Zucker-Franklin; E E Coutavas
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

8.  Sexual transmission of human T-cell leukemia virus type I associated with the presence of anti-Tax antibody.

Authors:  Y M Chen; A Okayama; T H Lee; N Tachibana; N Mueller; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.